Evaluation of an assay for MGMT gene promoter methylation in glioblastoma samples

Martin Filipits, Matthias Preusser, Johannes A. Hainfellner, Sabine Spiegl-Kreinecker, Anna S. Berghoff, Edwin W. Lai, Kriszten Kocmond, Andrew Kohlway, Jodi Weidler, Michael Bates, Christopher Corless

Research output: Contribution to journalArticlepeer-review


Background/Aim: To compare the GeneXpert® O6-methylguanine DNA methyltransferase (MGMT) methylation prototype (GX MGMT) assay with pyrosequencing in glioblastomas. Materials and Methods: The MGMT methylation status was retrospectively assessed in formalin-fixed paraffin embedded (FFPE) tumor blocks from 262 glioblastoma patients obtained from three independent cohorts using either a standard of care pyrosequencing laboratory developed test or the GX MGMT assay. Results: The concordance rate was 92.1% (58/63) for Oregon Health and Science University (OSHU) samples, 91.7% (88/96) for Medical University of Vienna (MUV) samples, and 82.5% (85/103) for Kepler University Hospital (KUH) samples. Patients with MGMT promoter hypermethylation assessed by pyrosequencing or the GX MGMT test had a significantly longer overall survival compared to patients without hypermethylation (HR=0.43, 95%CI=0.26-0.72, p=0.001 and HR=0.51, 95%CI=0.31-0.84, p=0.008, respectively). Conclusion: Standardized, simplified, and on-demand testing of MGMT promoter methylation by the GX MGMT assay is feasible.

Original languageEnglish (US)
Pages (from-to)6229-6236
Number of pages8
JournalAnticancer research
Issue number11
StatePublished - Nov 2020


  • GeneXpert
  • Glioblastoma
  • MGMT promoter methylation
  • Pyrosequencing

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Evaluation of an assay for MGMT gene promoter methylation in glioblastoma samples'. Together they form a unique fingerprint.

Cite this